Study Results for DARA BioSciences, Inc.’ Lead Drug for Neuropathic Pain, KRN5500, Selected for Presentation by the International Conference on Accelerating the Development of Enhanced Pain Treatments (“ADEPT”)

RALEIGH, N.C., Feb. 1, 2011 (GLOBE NEWSWIRE) -- The Company (Nasdaq:DARA) announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, “Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer.”